These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 36462127)

  • 1. Effects of biologic and target synthetic disease-modifying anti-rheumatic drugs on sarcopenia in spondyloarthritis and rheumatoid arthritis: a systematic review and meta-analysis.
    Ben Tekaya A; Mehmli T; Ben Sassi M; Teyeb Z; Bouden S; Rouached L; Mahmoud I; Dziri C; Abdelmoula L
    Clin Rheumatol; 2023 Apr; 42(4):979-997. PubMed ID: 36462127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis.
    Hasegawa E; Ito S; Kurosawa Y; Kobayashi D; Otani H; Abe A; Nakazono K; Murasawa A; Narita I; Ishikawa H
    Intern Med; 2023; 62(3):373-379. PubMed ID: 36725065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis.
    Hein TR; Peterson L; Bartikoski BJ; Portes J; Espírito Santo RC; Xavier RM
    Arthritis Res Ther; 2022 Jul; 24(1):171. PubMed ID: 35854372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of biological disease-modifying antirheumatic drugs on body composition in patients with rheumatoid arthritis: a systematic review and meta-analysis.
    de Souza MPGUES; Guimarães NS; de Resende Guimarães MFB; de Souza VA; Kakehasi AM
    Adv Rheumatol; 2022 May; 62(1):16. PubMed ID: 35606888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic and targeted synthetic disease-modifying anti-rheumatic drugs improve body composition in rheumatoid arthritis patients more than conventional synthetic disease-modifying anti-rheumatic drugs: Results from the PRESENT study.
    Tada M; Matsumoto Y; Koike T; Mamoto K; Nakamura T; Anno S; Iida T; Goto H; Hidaka N
    Int J Rheum Dis; 2024 Oct; 27(10):e15371. PubMed ID: 39381837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta-Analysis.
    Wetzman A; Lukas C; Gaujoux-Viala C; Mamtani R; Barnetche T; Combe B; Morel J; Szafors P
    Arthritis Care Res (Hoboken); 2023 Feb; 75(2):260-271. PubMed ID: 34549898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
    Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
    Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Sarcopenia and its Association with Antirheumatic Drugs in Middle-Aged and Older Adults with Rheumatoid Arthritis: A Systematic Review and Meta-analysis.
    Dao T; Kirk B; Phu S; Vogrin S; Duque G
    Calcif Tissue Int; 2021 Nov; 109(5):475-489. PubMed ID: 34132852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis.
    Uhrenholt L; Christensen R; Dinesen WKH; Liboriussen CH; Andersen SS; Dreyer L; Schlemmer A; Hauge EM; Skrubbeltrang C; Taylor PC; Kristensen S
    Rheumatology (Oxford); 2022 Aug; 61(8):3107-3122. PubMed ID: 34864896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing clinician prescribing of disease-modifying anti-rheumatic drugs for inflammatory arthritis: A systematic review and thematic synthesis of qualitative studies.
    Lalor AF; Brooker JE; Rozbroj T; Whittle SL; Hill CL; Rowett D; Buchbinder R; O'Connor DA
    Semin Arthritis Rheum; 2022 Aug; 55():151988. PubMed ID: 35286905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis.
    Shan J; Zhang J
    Joint Bone Spine; 2019 Mar; 86(2):173-183. PubMed ID: 29635017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry.
    Min HK; Kim HR; Lee SH; Shin K; Kim HA; Park SH; Kwok SK
    Clin Rheumatol; 2021 Aug; 40(8):3105-3113. PubMed ID: 33576925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with sarcopenia in Japanese patients with rheumatoid arthritis: results from the IORRA cohort study.
    Nakayama M; Furuya T; Inoue E; Tanaka E; Ikari K; Yamanaka H; Harigai M
    Clin Rheumatol; 2024 Jan; 43(1):521-526. PubMed ID: 37731082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
    Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
    Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.
    Bengtsson K; Jacobsson LT; Rydberg B; Kvist G; Torstenson T; Dehlin M; Hilme E; Lindhé A; Wallerstedt SM; Forsblad-d'Elia H
    BMC Musculoskelet Disord; 2016 Dec; 17(1):499. PubMed ID: 27955647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Ishikawa Y; Hashimoto M; Ito H; Tanaka M; Yukawa N; Fujii T; Yamamoto W; Mimori T; Terao C
    Semin Arthritis Rheum; 2019 Oct; 49(2):204-210. PubMed ID: 30803720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between biologic therapy and fracture incidence in patients with selected rheumatic and autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials.
    Lv F; Hu S; Lin C; Cai X; Zhu X; Ji L
    Pharmacol Res; 2022 Jul; 181():106278. PubMed ID: 35644324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis.
    Choy EH
    Rheumatology (Oxford); 2019 Nov; 58(Suppl 5):v51-v55. PubMed ID: 31682274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer.
    Pundole X; Zamora NV; Siddhanamatha H; Lin H; Tayar J; Hong LC; Li L; Suarez-Almazor ME
    Clin Rheumatol; 2020 Mar; 39(3):787-794. PubMed ID: 31853733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis.
    Torii M; Hashimoto M; Hanai A; Fujii T; Furu M; Ito H; Uozumi R; Hamaguchi M; Terao C; Yamamoto W; Uda M; Nin K; Morita S; Arai H; Mimori T
    Mod Rheumatol; 2019 Jul; 29(4):589-595. PubMed ID: 30092163
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.